Condition: Pediatric Acute Lymphoblastic Leukemia · Sponsor: Jae Wook Lee
* Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3. BM MRD ≥ 0.01% after Consolidation <!-- --> 1. T cell ALL : Change to very high risk regimen 2. Pre-B ALL : IM #1 → Intensification 1. BM MRD \< 0.01% after IM #1 : DI #1 → IM #2 → DI #2 → Maintenance 2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen * Difference in the number of \'interim maintenance(IM)\' and \'delayed intensification(DI)\' is important for chemotherapies based on MRD.
This description comes directly from the study's public registry record.
Jae Wook Lee, Ph.D · 82-2-2258-6192 · dashwood@catholic.ac.kr
Always discuss trial participation with your own doctor first.
| Seoul National University Hospital | Seoul, Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, Seoul, South Korea | Recruiting |
| Korea University Anam Hospital | Seoul, South Korea | Not Yet Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Seoul saint Mary's Hospital | Seoul, South Korea | Recruiting |
| Pusan National University Yangsan Hospital | Yangsan, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06184009